Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

202
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
202
Depression: Overview01:18

Depression: Overview

326
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
326
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

316
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
316
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

710
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
710
Long-term Depression01:03

Long-term Depression

2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.6K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

401
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
401

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychosocial and Psychopharmacological Interventions for Comorbid Bipolar Disorder and Substance Use Disorders: A Review.

Psychiatric annals·2025
Same author

Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline <i>APOBEC3B</i> deletion: results of the phase II AUROR study.

The Lancet regional health. Western Pacific·2025
Same author

Early antibiotic exposure and risk of psychiatric and neurocognitive outcomes: systematic review and meta-analysis: commentary, Green et al.

The British journal of psychiatry : the journal of mental science·2025
Same author

Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients With Major Depressive Disorder.

Journal of clinical psychopharmacology·2025
Same author

Preliminary efficacy of prolonged exposure therapy to reduce suicide risk in co-occurring bipolar disorder & trauma symptoms.

Journal of affective disorders·2025
Same author

Estimating the 12-Hour Serum Lithium Level (eLi<sub>12</sub>): Development and Two Proof-of-Concept Studies.

The Journal of clinical psychiatry·2025

Related Experiment Video

Updated: Aug 31, 2025

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.0K

Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial.

David Mischoulon1,2,3, Boadie W Dunlop4,2, Becky Kinkead4

  • 1Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.

The Journal of Clinical Psychiatry
|August 25, 2022
PubMed
Summary

High-dose eicosapentaenoic acid (EPA) may improve major depressive disorder (MDD) symptoms in overweight adults with inflammation. A 4g/day dose showed a medium effect size for response rates and correlated with reduced inflammatory markers.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

169
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

772

Related Experiment Videos

Last Updated: Aug 31, 2025

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.0K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

169
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

772

Area of Science:

  • Nutritional Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Major Depressive Disorder (MDD) is often associated with elevated inflammatory biomarkers.
  • Obesity and inflammation are recognized as contributing factors to MDD.
  • Eicosapentaenoic acid (EPA), an omega-3 fatty acid, has potential anti-inflammatory and mood-regulating properties.

Purpose of the Study:

  • To compare the efficacy of three different doses of EPA against a placebo in reducing inflammatory markers and depressive symptoms in adults with MDD.
  • To determine if EPA treatment leads to a significant reduction in specific inflammatory biomarkers, including IL-6 and TNF.
  • To assess the impact of EPA on depressive symptom severity, using the Inventory of Depressive Symptomatology, Clinician-Rated version (IDS-C30).

Main Methods:

  • A randomized, placebo-controlled trial involving 61 unmedicated adults with MDD, overweight status (BMI > 25 kg/m²), and elevated hs-CRP (≥ 3.0 mg/L).
  • Participants were assigned to receive EPA at 1 g/d, 2 g/d, 4 g/d, or placebo for 12 weeks.
  • Primary endpoints included effect size reductions in plasma IL-6, PBMC cytokines, and TNF production, alongside response rates defined by a ≥ 50% decrease in IDS-C30 scores.

Main Results:

  • Only the 2 g/d EPA dose showed a median decrease in peripheral blood mononuclear cell (PBMC) TNF. No EPA dose achieved the prespecified effect size for reducing plasma IL-6 or stimulated TNF.
  • The 4 g/d EPA dose yielded a response rate of 64%, compared to 40% for placebo (OR = 2.63, Cohen's d = 0.53), with lower rates for 1 g/d and 2 g/d EPA.
  • A significant correlation was observed between the percentage decrease in plasma hs-CRP and IDS-C30 symptom reduction at 12 weeks for the 4 g/d EPA group (Spearman ρ = 0.691, P = 0.019).

Conclusions:

  • Eicosapentaenoic acid (EPA) at a 4 g/d dose demonstrated a medium effect size for improving response rates in overweight individuals with MDD and elevated inflammatory markers.
  • The reduction in high-sensitivity C-reactive protein (hs-CRP) levels was significantly correlated with clinical improvement in depressive symptoms.
  • The 4 g/d EPA dose shows potential as an adjunctive treatment for MDD in this specific patient population, warranting further investigation.